相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
Rajiv Agarwal et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
Nelleke Snelder et al.
CLINICAL PHARMACOKINETICS (2020)
Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda
Panagiotis I. Georgianos et al.
CURRENT HYPERTENSION REPORTS (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment
Roland Heinig et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients
Fabian Hammer et al.
KIDNEY INTERNATIONAL (2019)
The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling
Daniel Lavall et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
David M. Charytan et al.
KIDNEY INTERNATIONAL (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study
Reimar W. Thomsen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo
Roland Heinig et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
Gianluigi Savarese et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity
Jana Grune et al.
HYPERTENSION (2018)
The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
Jonatan Barrera-Chimal et al.
KIDNEY INTERNATIONAL (2018)
Revisiting RAAS blockade in CKD with newer potassium-binding drugs
Panagiotis I. Georgianos et al.
KIDNEY INTERNATIONAL (2018)
Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study
Rajiv Agarwal et al.
AMERICAN JOURNAL OF NEPHROLOGY (2018)
Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
Michael Gerisch et al.
DRUG METABOLISM AND DISPOSITION (2018)
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
Robert M. Carey et al.
HYPERTENSION (2018)
Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
Raquel Gonzalez-Blazquez et al.
FRONTIERS IN PHARMACOLOGY (2018)
Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure
O. Ola Vedin et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB Pathway
Ernesto Martinez-Martinez et al.
HYPERTENSION (2017)
Mineralocorticoid receptor antagonists: 60 years of research and development
Peter Kolkhof et al.
JOURNAL OF ENDOCRINOLOGY (2017)
Diabetes with early kidney involvement may shorten life expectancy by 16 years
Chi Pang Wen et al.
KIDNEY INTERNATIONAL (2017)
Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence
Panagiotis I. Georgianos et al.
CURRENT VASCULAR PHARMACOLOGY (2017)
Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease Report From the Chronic Renal Insufficiency Cohort Study
George Thomas et al.
HYPERTENSION (2016)
The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis
Kevin Quach et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
Piotr Ponikowski et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction
Alexandre Gueret et al.
HYPERTENSION (2016)
Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
Jana Grune et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
Larbi Amazit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628
Frank Y. Ma et al.
PLOS ONE (2015)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Prevalence of Apparent Treatment-Resistant Hypertension among Individuals with CKD
Rikki M. Tanner et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
Stephen Orena et al.
FRONTIERS IN PHARMACOLOGY (2013)
Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms
Linda Shavit et al.
KIDNEY INTERNATIONAL (2012)
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
Peter Kolkhof et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
MH Weinberger et al.
AMERICAN JOURNAL OF HYPERTENSION (2002)
分享论文
